Cybersecurity firm Blue Coat Systems has decided to opt-out of an initial public offering and sell itself to software security leader Symantec for $4.65 billion.
Tag: patents on wall street
Contrarian patent investors see opportunity where others see risk
The emergence of contrarian patent investors – bargain hunters hoping to cash in on decidedly soft market for licensing and sales – are an indication that the
PIPCO stocks soar in a surprising first half for the second quarter
In what some patent holders are hoping will be a harbinger of things to come, publicly traded IP licensing companies are enjoying an unusually strong
Media use of patent “troll” is unfair says professor in Stanford Technology Law Review
The use of inaccurate, prejudicial language by newspapers, business publications and technology magazines to describe patent licensing activity biases readers and courts. That is among
The “new normal” is focus of IP Business Congress in Barcelona
With traditional patent strategies under pressure to show that they are still relevant, business as usual in the IP space is no longer the same.
Patent licensing index significantly outperformed the S&P 500 in Q1
The eagerly sought bottom for publicly traded patent licensing companies may have been reached according to the data provided by an intellectual property index that
Samsung is the leading US patent holder, 24,000 ahead of IBM
Of the top eleven active US patent holders, only four are American companies. But who gets the best return on their innovation rights is less
The impact of higher patent licensing hurdles may not be fully understood
Most patent holders would agree that licensing patents for revenue has gone from bad to awful — from difficult less than a decade ago, to
Jury awards Merck $200M in patent damages, 10% of what it had sought
A California jury has awarded pharmaceutical drug company Merck $200 million, a fraction of what it had sought, for infringement of two of its patents
Validated Merck patents could mean a $3B+ windfall, after appeals
While many high-tech patents are suffering from devaluation the value of some pharmaceutical patents is soaring. Merck & Co. won a legal victory over
“Secrets” is required reading for informed managers and investors
In an information age that worships data and transparency, the trade or business secret has never been more valuable. “Secrets” is an essential guide to
Technology companies back as top patent defendants in 2016
While it may seem like all of the patent infringement targets are large technology companies in 2015, at least 7 of the top 10 defendants
